Comparing immunosuppressive treatments for idiopathic membranous nephropathy
Official title: Different Immunosuppressive Treatment in Idiopathic Membranous Nephropathy: a Prospective Cohort
Run by Peking Union Medical College Hospital · NCT04745728 · Data updated 2026-11-12
This study is testing two different treatments for idiopathic membranous nephropathy to see which one helps patients feel better and stay well longer.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | rituximab, cyclophosphamide |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | April 14, 2021 |
| Main results expected | December 2027 |
| Study ends | December 2029 |
| Registry record updated | December 9, 2025 |
| Trial ID | NCT04745728 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are post-menopausal women with idiopathic membranous nephropathy who meet specific health criteria.
✕Probably not a fit
Patients with active infections, secondary causes of nephropathy, or those who have previously shown resistance to the treatments being tested may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to compare the effectiveness of two different immunosuppressive therapies for treating idiopathic membranous nephropathy (iMN) over a 24-month period. The therapies being compared are a combination of corticosteroids and cyclophosphamide versus rituximab, with a focus on determining the optimal dosing of rituximab. Previous studies have shown varying remission rates for these treatments, and this trial seeks to clarify which approach yields better long-term outcomes. Participants will be monitored for proteinuria levels and overall remission status throughout the study duration.
Why it matters
Potential benefit: If successful, this study could provide clearer guidance on the most effective treatment for patients with idiopathic membranous nephropathy, potentially leading to higher remission rates.
How similar studies have gone: Previous studies have shown varying success rates for similar treatment approaches, but this trial aims to provide a more definitive head-to-head comparison.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * idiopathic membranous nephropathy * Female, must be post-menopausal, sterile or have effective contraception * must be off steroid or mycophenolate mofetil for \>1 month and alkylating agents for or RTX\> 6 months * Angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for ≥ 3 months with controlled blood pressure prior to beginning of immunosuppressive therapy or if patients are intolerant to ACEI/ARB. * proteinuria ≥4g/24h and decreased ≤ 50% from baseline Exclusion Criteria: * presence of active infection or a secondary cause of membranous nephropathy * proteinuria associated with diabetic nephropathy * pregnancy or breast feeding * history of resistance to rituximab or alkylating agents or corticosteroid * Patients who previously achieved remission after treatment of rituximab or alkylating agents but relapsed off rituximab or alkylating agents after 6 months are eligible.
Where it's running
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Yan Qin — Peking Union Medical College Hospital
- Study coordinator: Sanxi Ai
- Email: sanxiai@163.com
- Phone: 18811054896
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Rivaroxaban to prevent blood clots in idiopathic membranous nephropathy
This trial will test whether daily rivaroxaban prevents dangerous blood clots better than warfarin in adults with idiopathic membranous nephropathy who have nephrotic syndrome and very low albumin.
-
Huaier granule treatment for idiopathic membranous nephropathy
This study is testing if Huaier granules can be a safe and effective treatment for people with idiopathic membranous nephropathy who haven't responded well to standard medications.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Glycogen Storage Disease and Brain Function in People Like You
This study tests whether people with glycogen storage disease perform differently on cognitive tests and show different brain imaging features compared with healthy peers.
-
FAPI PET Imaging to See Fibroblast Activity in Nonischemic Cardiomyopathy
This study tests whether a special PET/CT scan using 18F-AlF-NOTA-FAPI-04 can reveal active fibroblast activity in the hearts of adults with nonischemic cardiomyopathy to help understand disease behavior and guide care.
-
Ivonescimab with GEMOX as neoadjuvant and conversion therapy for biliary tract cancer
This study tests whether adding Ivonescimab to GEMOX can help patients with biliary tract cancer shrink tumors before surgery or enable conversion to operable disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.